EligibleTrials

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Recruiting · NCT06132893 · Interventional (participants receive a specific treatment) · Lead sponsor: Biohaven Therapeutics Ltd.

View the official record on ClinicalTrials.gov →
Epilepsy

Interventions studied

BHV-7000Placebo

What this trial is about

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

Who can take part

Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2, Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

60 locations listed across 26 US states.

Showing 60 of 124 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.